ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Feinstein Institutes Scientists Outline in Neuron Bioelectronic Medicine Advances, Future of Clinical Care

Scientists from The Feinstein Institutes for Medical Research, Kevin J. Tracey, MD, and Valentin Pavlov, PhD, published in Neuron findings of preclinical and clinical research in bioelectronic medicine, highlighting potential hope for patients who live with inflammatory diseases, cancer, diabetes, rheumatoid arthritis and other disorders. Treating these diseases without the use of traditional, often harmful, biologics may be possible with bioelectronic medicine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221010005549/en/

Valentin Pavlov, PhD, professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes, is one of the co-authors of the new article recently published in Neuron. (Credit: Feinstein Institutes)

Valentin Pavlov, PhD, professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes, is one of the co-authors of the new article recently published in Neuron. (Credit: Feinstein Institutes)

The Feinstein Institutes is the global scientific home of bioelectronic medicine. Investigators within the Institute of Bioelectronic Medicine at the Feinstein Institutes have studied the use of electricity to target nerves to control inflammation within the body for more than two decades. Bioelectronic medicine combines molecular medicine, neuroscience and biomedical engineering to develop innovative therapies to treat a variety of diseases and conditions through targeted stimulation of nerves, including paralysis, rheumatoid arthritis, pulmonary hypertension and inflammatory bowel disease.

“If we can control inflammation, we can control disease. As we have seen over the past 20 years, we can regain control of our body’s immune system through the use of electricity and targeting our nerves,” said Dr. Tracey, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. “We hope this paper acts as a roadmap for bioelectronic medicine researchers to navigate and discover ways to treat disease without drugs.”

In the article, Drs. Tracey and Pavlov outline breakthrough discoveries made in the lab and how they translate to clinical care today. For example, a discovery made by Dr. Tracey and colleagues highlighted the role the vagus nerve plays in controlling our body’s immune response, known as the inflammatory reflex. Inflammation can be controlled through the vagus nerve – the body’s main highway of neural information that prompts and curbs our body’s immune response and the release of often harmful inflammatory molecules. By modulating this neural reflex circuit with electricity, researchers have shown the ability to stop those harmful inflammatory proteins and return the body to maintain homeostasis.

“Bioelectronic medicine has emerged as a field driven by progress in neuroscience and many other disciplines. Discovering molecular targets controlled by nerves has allowed further research into the use of devices and other stimulation methods to treat disease,” said Dr. Pavlov, professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes. “While there is still plenty of work to be done, in the research lab and through clinical trials, it is encouraging to see the potential bioelectronic medicine has to help so many people.”

Drs. Pavlov and Tracey spotlight how lab bench discoveries, like the inflammatory reflex, are being put into clinical use. For example, new technology has led to improvements in the assembly, microfabrication, miniaturization and long-term stability of nerve implants along with advances in the design of electrode cuffs and the use of other flexible materials used to stimulate and record neural activity. Artificial intelligence (AI) allows large data sets to be generated, stored and analyzed to develop algorithms for identifying specific patterns, which is helpful in neuronal coding and mapping. AI and machine learning are critical in improving brain-machine interfaces to help people with neurological disorders as well as paralysis.

Optogenetics, or the use of light to stimulate nerves, as well as nerve implants, deep brain stimulation and ultrasound stimulation techniques are being explored in current clinical trials to help patients suffering from retinal diseases, inflammatory diseases, depression, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative and neuropsychiatric disorders.

Researchers at the Feinstein Institutes continue to make great strides in the field of bioelectronic medicine and continue to lead in communicating the research worldwide.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.56
+0.02 (0.01%)
AAPL  274.61
+0.50 (0.18%)
AMD  209.17
+1.59 (0.77%)
BAC  54.81
-0.52 (-0.94%)
GOOG  307.73
-1.59 (-0.51%)
META  657.15
+9.64 (1.49%)
MSFT  476.39
+1.57 (0.33%)
NVDA  177.72
+1.43 (0.81%)
ORCL  188.65
+3.73 (2.02%)
TSLA  489.88
+14.57 (3.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.